Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis

Europace

Volumn 13, Issue 5, 2011, Pages 723-746

  Lip, Gregory Y H ^a   Andreotti, Felicita ^b   Fauchier, Laurent ^c   Huber, Kurt ^d   Hylek, Elaine ^e   Knight, Eve ^f   Lane, Deirdre A ^a   Levi, Marcel ^f   Marin, Francisco ^g   Palareti, Gualtiero ^h   Kirchhof, Paulus ⁱ   Collet, Jean Philippe ^j   Rubboli, Andrea ^k   Poli, Daniela ^l   Camm, John ^m  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c SERVICE DE DERMATOLOGIE   (France)

^d Wilhelminenhospital   (Austria)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k MAGGIORE HOSPITAL   (Italy)

^l Thrombosis Centre   (Italy)

^m ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

Antithrombotic therapy; Atrial fibrillation; Bleeding; Oral anticoagulation; Risk assessment; Stroke prevention; Triple therapy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; COMORBIDITY; DEFIBRILLATOR; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; MEDICAL SOCIETY; PACEMAKER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STROKE; SYSTEMATIC REVIEW; THROMBOSIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; EUROPE; HEMORRHAGE; HUMANS; RISK FACTORS; SOCIETIES, MEDICAL; STROKE; THROMBOSIS;

EID: 79955439399     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur126     Document Type: Article

References (181)

1. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007;28:2803-17. (Pubitemid 350135529)
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360-420.
3. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.
4. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010;3:624-31.
5. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104:49-60.
6. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15.
7. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD et al., Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators. Stroke 2009;40:1410-6.
8. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72.
10. Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation al 'moderate risk' [CHADS2 score1/41]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103:683-5.
11. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-11. (Pubitemid 46849160)
12. Lin H, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ et al. Stroke severity in atrial fibrillation: The Framingham study. Stroke 1996;27:1760-4. (Pubitemid 26332500)
13. Flaherty MLKB, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007;68:116-21. (Pubitemid 46071894)
14. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH et al. on behalf of the Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018-26. (Pubitemid 44963431)
15. Mazzaglia G, Filippi A, Alacqua M, CowellW, Shakespeare A, Mantovani LG et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010;103:968-75.
16. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010;104:1099-105.
17. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J et al., the RE-LY Steering Committee and Investigators. Dabigatran and Warfarin in Vitamin K antagonist-naive and experienced cohorts with atrial fibrillation. Circulation 2010;122:2246-53.
18. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
19. SPAF Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-91.
20. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the AFFIRM Study. Am Heart J 2005;149: 650-6.
21. Executive Steering Committee for the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation. Lancet 2003;362:1691-8.
22. Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005;293:690-8.
23. Active Writing Group on behalf of the Active Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of vascular events. Lancet 2006;367:1903-12.
24. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al.; RE-LY Steering Committee and Investigators. Dabigatran vs.Warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
25. O'Riordan M. Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds. theheart.org. [Clinical Conditions.Arrhythmia/ EP.Arrhythmia/ EP]; 15November 2010. http://www.theheart.org/article/1148785.do (29 December 2010, date last accessed).
26. Landefeld CS, Goldman OL. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52. (Pubitemid 19201634)
27. Steffensen F, Kristensen K, Ejlersen E, Dahlerup J, Sorensen H. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997;242:497-503. (Pubitemid 28015722)
28. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9. (Pubitemid 28405230)
29. Pengo V, Legnani C, Noventa F, Palareti G, ISCOAT Study Group. Italian Study on Complications of Oral Anticoagulant Therapy. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleed. A multicenter inception cohort study. Thromb Haemost 2001;85:418-22. (Pubitemid 32233011)
30. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96. (Pubitemid 46842784)
31. Van Der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993;153:1557-62. (Pubitemid 23205854)
32. Fihn SD, McDonell M, Martin D. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993;118:511-20. (Pubitemid 23085793)
33. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003;290:2685-91.
34. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009;54:999-1002.
35. Rose A, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practice. J Thromb Haemost 2008;6:1647-54.
36. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999;14: 303-12. (Pubitemid 29195346)
37. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745-52.
38. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008;133: 257S-298S. (Pubitemid 351892969)
39. Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 2004;25:1734-40. (Pubitemid 39286639)
40. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007;154:3-11. (Pubitemid 46924806)
41. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54. (Pubitemid 17093202)
42. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-82.
43. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
44. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
45. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT et al. Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial investigators,Bivalirudin in patiens with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369:907-19. (Pubitemid 46400858)
46. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB et al., Oasis-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30.
47. Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C et al., for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
48. Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G et al. The Outpatient Bleeding Risk Index: validation of a tool for predicting bleeding rates in patients treated for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2003;163:917-20. (Pubitemid 36519737)
49. Kuijer PMM, Hutten BA, Prins MH et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159:457-60. (Pubitemid 29108910)
50. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4. (Pubitemid 41647882)
51. Aspinall SL, De Sanzo BE, Trilli LE, Good CB. Bleeding risk index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med 2005;20:1008-13. (Pubitemid 41726654)
52. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW et al. Clinical classification schemes for predicting haemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-9. (Pubitemid 43290267)
53. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006;130:1390-6. (Pubitemid 44786731)
54. Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL et al., RIETE Investigators. Predictive variables for major bleeding events inpatients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:26-31. (Pubitemid 351952971)
55. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A et al., and on behalf of the Academic Research Consortium. Clinical End Points in Coronary Stent Trials: A case for standardized definitions. Circulation 2007;115:2344-51. (Pubitemid 46685903)
56. Palareti G, Cosmi B. Bleeding with anticoagulation therapy-Who is at risk, and how best to identify such patients. Thromb Haemost 2009;102:268-78.
57. Hughes M, Lip GY, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007;100:599-607.
58. Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202-4.
59. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-82. (Pubitemid 44268228)
60. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schöming A et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-7. (Pubitemid 351221218)
61. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997;95:2508-16.
62. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-23. (Pubitemid 37280247)
63. Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG. Canadian Acute Coronary Syndromes Registries Investigators. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005;150:690-4. (Pubitemid 41396500)
64. Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke 2009;40:2068-72.
65. Rosand J, Echman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4. (Pubitemid 38520629)
66. Michel P, Odier C, Rutgers M, Reichhart M, Maeder P, Meuli R et al. The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging. Stroke 2010; 41:2491-8.
67. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-62. (Pubitemid 39314961)
68. Arioldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L et al. Circulation 2007;116:745-54.
69. Kinnaird T, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-5. (Pubitemid 37214804)
70. Collet JP, Montalescot G. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit? Int J Cardiol 2009;133:8-17.
71. Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med. 2010;77:791-9.
72. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322: 428-32. (Pubitemid 20059511)
73. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8. (Pubitemid 26267872)
74. Vink R, Kraaijenhagen RA, Hutten BA, van den Brink RB, de Mol BA, Buller HR et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol 2003;42:2042-8. (Pubitemid 37549882)
75. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902. (Pubitemid 24179151)
76. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
77. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167: 239-45.
78. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
79. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66.
80. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS et al., THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010;363:1608-20.
81. Levi M, de Peuter OR, Kamphuisen PW. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Semin Thromb Hemost 2009;35:560-7.
82. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287: 1690-8. (Pubitemid 34289221)
83. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005;2:e312.
84. Namazi S, Azarpira N, Hendijani F, Khorshid MB, Vessal G, Mehdipour AR. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin Ther 2010;32:1050-60.
85. Lip GYH. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Europace 2011;13:145-8.
86. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008;111:4471-6.
87. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999;9:215-7. (Pubitemid 29308806)
88. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-50.
89. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006;333:726.
90. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-74.
91. Mellemkjaer L, Blot WJ, Sorensen HT, Thomassen L, McLaughlin JK, Nielsen GL et al. Upper gastrointestinal bleeding among users of NSAIDs: a populationbased cohort study in Denmark. Br J Clin Pharmacol 2002;53:173-81. (Pubitemid 34264272)
92. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005;165:189-92.
93. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;159:677-85. (Pubitemid 29177656)
94. Levi M, Hovingh K. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Thromb Haemost 2008;100: 1047-51.
95. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess one year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010;138:1093-100.
96. Fang M, Go A, Chang Y, Borowsky LH, Pmernacki NK, Udaltsova N et al. Abstract 16443: Development of a new risk stratification scheme to predict warfarin-associated hemorrhage: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 2010;122:A16443.
97. Lip GY, Frison L, Halperin JL, Lane D. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score. J Am Coll Cardiol 2011;57:173-80.
98. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee. Canadian cardiovascular society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27:74-90.
99. Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GYH. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006;110:354-8. (Pubitemid 43831214)
100. Lip GYH, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ. Oral anticoagulation in atrial fibrillation: a Pan-European Patient Survey. Eur J Intern Med 2007;18: 202-8. (Pubitemid 46628758)
101. Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract 2004; 5:15.
102. Department of Health. Patient and Public Involvement in the New NHS. London: Department of Health 1999.
103. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. J Am Med Assoc 1995;274:1839-45. (Pubitemid 26001259)
104. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-36. (Pubitemid 26295228)
105. Man Son Hing M, Laupacis A, O'Connor A, Wells G, Lemelin J, Wood W et al. Warfarin for atrial fibrillation: The patient's perspective. Arch Intern Med 1996; 156:1841-8. (Pubitemid 26295230)
106. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with non-valvular atrial fibrillation. Stroke 1998;29:1083-91. (Pubitemid 28265459)
107. Sudlow M, Thomson R, Kenny RA, Rodgers H. A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences. Br J Gen Pract 1998;48:1775-8. (Pubitemid 28508442)
108. Man-Son-Hing M, Laupacis A, O'Connor AM, Biggs J, Drake E, Yetisir E et al., for the Stroke Prevention in Atrial Fibrillation Investigators. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomised controlled trial. J Am Med Assoc 1999;282:737-43. (Pubitemid 29404379)
109. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. Br Med J 1999;318:1324-7. (Pubitemid 29219046)
110. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. Br Med J 2000;320:1380-4. (Pubitemid 30261119)
111. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000;355:956-62. (Pubitemid 30148260)
112. McAlister FA, Man Son Hing M, Straus SE, GhaliWA, Anderson D, Majumdar SR et al., for the Decision Aid in Atrial Fibrillation (DAAFI) Investigators. Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ 2005;173:496-501. (Pubitemid 41225044)
113. Thomson RG, Eccles MP, Steen IN, Greenaway J, Stobbart L, Murtagh MJ et al. A patient decision aid to support shared decision-making on antithrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care 2007;16:216-23. (Pubitemid 46972867)
114. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation; observational study. Br Med J 2001;323:1-7.
115. Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation- semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin. Age Ageing 2004;33:608-11. (Pubitemid 39504295)
116. Man Son Hing M, O'Connor AM, Drake E, Biggs J, Hum V, Laupacis A. The effect of qualitative vs. quantitative presentation of probability estimates on patient decision-making: a randomised trial. Health Expect 2002;5:246-55. (Pubitemid 34988190)
117. Holbrook A, Labiris R, Goldsmith CH, Ota K, Harb S, Sebaldt RJ. Influence of decision aids on patient preferences for anticoagulant therapy: a randomised trial. Can Med Assoc J 2007;176:1583-7. (Pubitemid 46868606)
118. Alonso-Coello P, Montori VM, Solà I, Schünemann HJ, Devereaux PJ, Charles C et al. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. BMC Health Serv Res 2008;8:221-33.
119. Fuller R, Dudley N, Blacktop J. Risk communication and older people-understanding of probability and risk information by medical inpatients aged 75 years and older. Age Ageing 2001;30:473-6. (Pubitemid 34071486)
120. Thrall G, Lane DA, Carroll D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448.e1-19.
121. Aliot E, Briethardt G, Brugada J, Camm J, Lip GYH, Vardas PE,Wagner M for the Atrial Fibrillation Awareness and Risk Education (AF AWARE) group [comprising the Atrial Fibrillation Association (AFA), the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart Federation (WHF)]. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace 2010;12:626-33.
122. Calkins H, Yong P, Miller JM, Olshansky B, Carlson M, Saul JP et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999;99:262-70. (Pubitemid 29056369)
123. Finlay M, Sawhney V, Schilling R, Thomas G, Duncan E, Hunter R et al. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy. J Cardiovasc Electrophysiol 2010;21: 150-4.
124. Alvarez-Lopez M, Rodriguez-Font E, Garcia-Alberola A, Spanish Catheter Ablation Registry. Fifth official report of the Spanish Society of Cardiology Working Group on Electrophysiology and Arrhythmias (2005). Rev Esp Cardiol 2006;59: 1165-74. (Pubitemid 46139213)
125. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic internatioinal normalized ratio. Circulation 2010;121:2550-6.
126. Gaita F, Caponi D, Pianelli M, Scaglione M, Toso E, Cesarani F et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of siltent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010;122:1667-73.
127. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32-8.
128. Blanc JJ, Almendral J, Brignole M, Fatemi M, Gjesdal K, Gonzalez-Torrecilla E et al. Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. Europace 2008;10:513-27. (Pubitemid 351775308)
129. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009;6:1425-9.
130. Schmidt M, Segerson NM, Marschang H, Akoum N, Rittger H, Clifford SM et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2009;32:995-9.
131. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010;122:2368-77.
132. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G et al., Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease. The task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J 2007;28: 230-68. (Pubitemid 46276943)
133. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC et al., American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl.):299S-339S. (Pubitemid 351894915)
134. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004;109:997-1003. (Pubitemid 38292177)
135. Hirsh J, Bauer K, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College Of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141S-159S. (Pubitemid 351892966)
136. Thal S, Moukabary T, Boyella R, Shanmugasundaram M, Pierce MK, Thai H et al. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation. Pacing Clin Electrophysiol 2010;33:385-8.
137. Giudici MC, Paul DL, Bontu P, Barold SS. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol 2004;27:358-60. (Pubitemid 38352516)
138. Wiegand UK, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Schunkert H et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004;126:1177-86. (Pubitemid 39391248)
139. Michaud GF, Pelosi F Jr, Noble MD, Knight BP, Morady F, Strickberger SA. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. J Am Coll Cardiol 2000;35:1915-8. (Pubitemid 30342875)
140. Robinson M, Healey JS, Eikelboom J, Schulman S, Morillo CA, Nair GM et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol 2009;32:378-82.
141. Jamula E, Douketis JD, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost 2008;6:1615-21.
142. Tolosana JM, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009; 30:1880-4.
143. Dreger H, Grohmann A, Bondke H, Gast B, Baumann G, Melzer C. Is antiarrhythmia device implantation safe under dual antiplatelet therapy? Pacing Clin Electrophysiol 2010;33:394-9.
144. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H et al., European Society of Cardiology; European Heart Rhythm Association. Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace 2007;9:959-98.
145. Lip G, Huber K, Andreotti F, Arnesen H, Airaksinen K, Cuisset T et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010;103:13-28.
146. Agostoni P, Biondi-Zoccai G, de Benedictis M, Rigattieri S, Turri M, Anselmi M et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic Overview and Meta-analysis of Randomized Trials. J Am Coll Cardiol 2004;44:349-56. (Pubitemid 38950594)
147. Jolly S, Amlani S, Hamon M, Yusuf S, Mehta S. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 2009;157:132-40.
148. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102: 1618-23.
149. Sarafoff N, Ndrepepa G, Mehilli J, Dö rrler K, Schulz S, Iijima R et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008;264: 472-80.
150. Bhatt D, Scheiman J, Abraham N, Antman E, Chan F, Furberg C et al. ACCF/ ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:1502-17.
151. Silber S, Albertsson P, Aviles F, Camici PG, Colombo A, Hamm CW et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804-47.
152. Cuisset T, Valgimigli M, Mudra H, Muller O, Wijns W, Huber K. Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention 2010;6:39-45.
153. Ho P, Peterson E, Wang L, Magid D, Fihn S, Larsen G et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9. (Pubitemid 351222546)
154. Nuttall G, Brown M, Stombaugh J, Michon P, Hathaway M, Lindeen K et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 2008;109:588-95.
155. Rabbitts J, Nuttall G, Brown M, Hanson A, Oliver W, Holmes D et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 2008;109:596-604.
156. Metzler H, Kozek-Langenecker S, Huber K. Antiplatelet therapy and coronary stents in perioperative medicine-the two sides of the coin. Best Pract Res Clin Anaesthesiol 2008;22:81-94. (Pubitemid 351418963)
157. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP et al. TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;19: 1353-63.
158. Fleisher L, Beckman J, Brown K, Calkins H, Chaikof E, Fleischmann K et al. ACC/ AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2007;116:e418-499.
159. Samama MM, Horellou MH, Achkar A, Conard J; collaboration de F Mauriat. Perioperative use of antithrombotic agents: recommendations of the American College of Chest Physicians (ACCP) and the French Superior Health Authority (HAS). J Mal Vasc 2010;35:220-34.
160. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85.
161. Oscarsson A, Gupta A, Fredrikson M, Järhult J, Nyström M, Pettersson E et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010;104:305-12.
162. Grines C, Bonow R, Casey DJ, Gardner T, Lockhart P, Moliterno D et al. American Heart Association; American College of Cardiology; Society for Cardiovascular. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 2007;138:652-5.
163. Savonitto S, D'Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010;104:285-91.
164. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008;133: 160S-198S. (Pubitemid 351892967)
165. Ananthasubramaniam K, Beattie JN, Rosman HS et al. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest 2001;119:478-84. (Pubitemid 32163760)
166. Hackman DG, Kopp A, Redelmeier DA. Prognostic implications of warfarin cessation after major trauma. A population-based cohort analysis. Circulation 2005; 111:2250-6. (Pubitemid 40632442)
167. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006;4:1853-63. (Pubitemid 44226758)
168. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin. Ann Intern Med 2009;150:293-300.
169. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002;20:251-4.
170. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003;163:2469-73. (Pubitemid 37385789)
171. van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, de Vries-Goldschmeding HJ, Rakers E, Levi M. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon. Thromb Haemost 2007;98:747-55. (Pubitemid 47555065)
172. Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007;82:82-92. (Pubitemid 46036324)
173. van AL, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006;118:313-20. (Pubitemid 44173049)
174. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008;6:622-31. (Pubitemid 351404929)
175. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-5. (Pubitemid 47326459)
176. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10 year compilation of thrombotic adverse events. Haemophilia, 2002; 8: 83-90. (Pubitemid 35238060)
177. Bonow RO, Carabello BA, Kanu C et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006;48:e1-148. (Pubitemid 44109952)
178. Kanderian AS, Gillinov M, Pettersson GB, Blackstone E, Klein AL. Success of surgical left atrial appendage closure. Assessment by transesophageal echocardiography. J Am Coll Cardiol 2008;52:924-9.
179. Ostermayer SH, Reisman M, Kramer PH, Matthews RV, Gray WA, Block PC et al. Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005;46:9-14. (Pubitemid 40905122)
180. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M et al.; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised noninferiority trial. Lancet 2009;374:534-42.
181. Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K et al. Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation-Initial European experience. Catheter Cardiovasc Interv 2011;77:700-6.